drugset / Trial / NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Timeline
- Start
- 2025-02-17
- Primary completion
- 2029-01-04
- Completion
- 2029-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986482 | Unknown | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |
| Subject | Relatlimab | Monoclonal antibody | — | — |
| Subject | rHuPH20 | Protein / enzyme biologic | — | — |